Skip to main content

Podofilox topical Pregnancy and Breastfeeding Warnings

Brand names: Condylox

Medically reviewed by Drugs.com. Last updated on Jul 10, 2023.

Podofilox topical Pregnancy Warnings

Podofilox topical has been assigned to pregnancy category C by the FDA. Animal studies have revealed evidence of embryotoxicity at a dose 250 times the maximum human dose. There are no controlled data in human pregnancy. Podofilox topical is only recommended for use during pregnancy when benefit outweighs risk.

See references

Podofilox topical Breastfeeding Warnings

There are no data on the excretion of podofilox topical into human milk. The manufacturer recommends that due to the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue podofilox topical, taking into account the importance of the drug to the mother.

See references

See also

References for pregnancy information

  1. (2006) "Product Information. Podofilox Topical (podofilox topical)." Paddock Laboratories Inc
  2. (2006) "Product Information. Condylox (podofilox topical)." Oclassen Dermatologics

References for breastfeeding information

  1. (2006) "Product Information. Podofilox Topical (podofilox topical)." Paddock Laboratories Inc
  2. (2006) "Product Information. Condylox (podofilox topical)." Oclassen Dermatologics

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer